This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Barrett's oesophagus and risk of oesophageal adenocarcinoma or oesophageal cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Risk of adenocarcinoma of the oesophagus:

Oesophageal adenocarcinoma (AC) risk is more than 11 times higher in people with Barrett's oesophagus (BO) versus the general population, a cohort study showed.[1]

Oesophageal AC develops in around 1 per 1,000 BO patients per year [1,2]

  • on the basis of these risk levels 3-10% of people with Barrett’s oesophagus in the UK will develop oesophageal AC in their lifetime

However, previous studies estimate a much higher risk of around 1 oesophageal AC case per 160-190 BO patients per year.[4,5]

  • on the basis of these risk levels 7-13% of people with Barrett’s oesophagus in the UK will develop oesophageal AC in their lifetime.[3]

Oesophageal AC risk among BO patients increases with BO extent (higher in long-segment than short-segment) and severity (progressively higher through non-dysplastic[4,6] low-grade dysplastic or high-grade dysplastic).

Oesophageal AC risk among BO patients may be higher in males than females, and in smokers than non-smokers.[7]

Factors affecting risk of oesophageal AC if BO:

  • risk of oesophageal AC or BO with high-grade dysplasia, among BO patients, is 71% lower in those using proton pump inhibitors (PPIs), and 36% lower in those using cyclooxygenase (COX) inhibitors, versus non-users, meta-analyses have shown.[8,9]

  • risk reduction with PPI use may be greater in, or limited to, longer-term use.[8]

  • oesophageal AC risk among BO patients is 36% lower in non-steroidal anti-inflammatory drugs (NSAIDs) users versus non-users, and 41-47% lower in statin users, both compared with non-users, meta-analyses have shown.[10-13]
    • risk reduction with statins may be limited to those with high-grade dysplasia and may be confounded by NSAIDs use

Reference


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.